Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at…
Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) (‘Forum’ or the ‘Company’) announced today that the Company is not…
(TheNewswire) December 19th, 2024 TheNewswire – Vancouver, B.C. Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’…
Westgold Resources (ASX:WGX,TSX:WGX,OTCQX:WGXRF) has completed a scoping study that evaluates an expansion of its Fortnum gold operation in Western…
Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here.…
The US Federal Reserve announced an interest rate cut of 25 basis points on Wednesday (December 18), reducing its…
Cyprium Metals Limited (ASX: CYM, OTC: CYPMF) (Cyprium or the Company) is pleased to announce the successful completion of…
Opawica Exploration (TSXV:OPW) is a Vancouver-based junior exploration company exploring and developing precious metal properties in Canada. Opawica’s flagship…